+7 (495) 414-60-88

Moscow, 3rd Cherepkovskaya str. 15A

Location map




Nikavir (Phosfazid) - a new domestic противоретровирусный the drug.

Nikavir (Phosfazid) - a new domestic противоретровирусный the drug.

Central research Institute of epidemiology of Ministry of health of the Russian Federation, the Federal scientific and methodological centre of the Ministry of health of the Russian Federation for the prevention and fight against AIDS, Moscow.

With a view to ascertaining the safety and effectiveness of new domestic противоретровирусного preparation Никавир (Фосфазид) for the treatment of patients with HIV-infection conducted multicenter clinical laboratory observation of the 103 adults with HIV infection receiving фосфазид during 12 weeks. Studied 4 of the scheme of reception of a preparation - 0,2 g 2 times per day, to 0.2 g 3 times a day, 0.4 g 2 times a day, 0.4 g 3 times a day. The therapeutic effect is revealed in all modes of intake of the drug: a decrease in the concentration of HIV RNA already by the end of the 2nd week of treatment 0.51 log10 and increase the number of CD4 t-cells by 0.1•10 9/l. The most frequent side effect of therapy are слабовыраженная nausea and weakness. It is possible to use фосфазида in patients with previously observed intolerance derivatives AZT, anemia, and thrombocytopenia, гранулоцитопенией. The standard can be recommended scheme of reception of a preparation 0.4 g 2 times a day.

«Epidemiology and infectious diseases» №1 p. 43, 2001.



google_analitics